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P2Y12 Receptor Blockade and
Myocardial Perfusion*Paul A. Gurbel, MD, Udaya S. Tantry, PHD
Baltimore, Maryland
The major goal of percutaneous coronary revascularization is
the establishment of durable myocardial perfusion. In the
setting of acute coronary syndromes (ACS), there is target
lesion instability largely caused by a local and systemic pro-
thrombotic milieu. A state of vulnerable vessel and vulnerable
blood is present in ACS: 1) unstable coronary lesions are rich
in adhesion molecules and agonists that interact with plate-
lets and 2) circulating platelets are highly reactive. One of the
key agonists responsible for platelet activation, sustained
expression of the activated glycoprotein (GP) IIb/IIIa
receptor, resultant ampliﬁcation of platelet aggregation, and
thrombus stabilization is adenosine diphosphate (ADP). The
surface of the activated platelet is an important site for
coagulation factor generation and speciﬁc molecules that
modulate procoagulant and proinﬂammatory properties of
leukocytes. These core mechanistic concepts have served as
the rationale for pharmacologically inhibiting the major
platelet ADP receptor, P2Y12, in patients with high-risk
coronary artery disease during the past 22 years (1).See page 671Platelet-mediated thrombosis is believed to play a role in
the occurrence of post-percutaneous coronary intervention
(PCI) microvascular obstruction and subsequent myocardial
infarction (MI). In autopsy studies, platelet aggregates
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perfusion is the TIMI (Thrombolysis In Myocardial
Infarction) myocardial perfusion (TMP) scale that was pio-
neered by the senior author of the current paper (3,4). This
angiographic technique assesses the ﬁlling and clearance of
contrast in the myocardium and was ﬁrst reported in a study
of patients treated with TNK–tissue-type plasminogen acti-
vator (t-PA) compared with front-loaded alteplase in patients
with acute MI in the TIMI 10B trial. Four TMP grades
(TMPGs) were deﬁned, with TMPG 0 being no tissue-level
perfusion (no blush or opaciﬁcation of the myocardium) in
the distribution of the culprit artery; TMPG 1 being the
myocardial blush but no clearance from the microvasculature;
TMPG 2 being slow blush clearance, and TMPG 3 being
present when blush began to clear during washout. In this
landmark paper, a mortality gradient across the TMPGs was
observed, with mortality being lowest in those patients with
TMPG 3, intermediate in TMPG 2, and highest in TMPGs
0 and 1 (3). The TMPG has been used extensively in clinical
studies. In the setting of unstable angina/non–ST-segment
elevation myocardial infarction (STEMI), post-procedural
troponin I elevations have been associated with low TMPG.
In the CLARITY–TIMI 28 (Clopidogrel as Adjunctive
Reperfusion Therapy – Thrombolysis in Myocardial Infarc-
tion 28) angiographic substudy, the presence of residual
thrombus after ﬁbrinolytic therapy for STEMI was also
associated with a lower rate of normal TMPG (5).
The utility of platelet inhibition in preserving myocardial
perfusion has been previously investigated. The most widely
studied platelet inhibitors have been the GPIIb/IIIa inhib-
itors (GPIs). Although these inhibitors target the ﬁnal
pathway leading to platelet aggregation, their effects on
platelet activation remain controversial. In vitro studies of
GPIs have demonstrated their ability to disaggregate plate-
lets. In studies in which platelet thrombi were formed on
a collagen surface after whole-blood perfusion, the addition
of a GPI (abciximab, eptiﬁbatide, or tiroﬁban) resulted
in thrombi dissolution (6). In the PROTECT–TIMI-30
(Randomized Trial to Evaluate the Relative PROTECTion
against Post-PCI Microvascular Dysfunction and Post-
PCI Ischemia among Anti-Platelet and Anti-Thrombotic
Agents–Thrombolysis In Myocardial Infarction-30) trial,
the administration of eptiﬁbatide to patients with unstable
angina/non-STEMI undergoing PCI was associated more
often with a normal post-PCI TMPG than bivalirudin
therapy (7). Upstream administration versus post-PCI ad-
ministration of tiroﬁban has been associated with improved
TMPG (8). In a substudy of the INTEGRITI (Integrilin
and Tenecteplase in Acute Myocardial Infarction) trial,
in which low-dose tenecteplase was administered with
eptiﬁbatide, high GPIIb/IIIa receptor occupancy was asso-
ciated with optimal TMPG (9). All of the above evidence
of superior myocardial perfusion associated with potent
platelet inhibition further supports the key role that platelet
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685physiology plays in microvascular occlusion in the high-risk
coronary artery disease patient.
It has also been reported that P2Y12 inhibitors disaggre-
gate platelets. In ex vivo studies using confocal video
microscopy to measure real-time platelet thrombi formation
over collagen in the presence of shear, disaggregation of
platelet thrombi was observed in the blood of patients on
long-term thienopyridine and aspirin therapy (10). In
contrast to GPIs, the role of P2Y12 inhibitors in inhibiting
platelet activation and procoagulant effects is more estab-
lished. P2Y12 inhibitors have also been investigated as
facilitators of myocardial perfusion in the PCI patient. In the
ERASE MI (Early Rapid ReversAl of platelet thromboSis
with intravenous Elinogrel before PCI to optimize reper-
fusion in acute Myocardial Infarction) trial (n ¼ 92),
increasing doses of intravenous elinogrel in STEMI patients
were not associated with an improvement in the pre-PCI
corrected TIMI frame count (CTFC) (11). In the STEP-
AMI trial, the combination of increasing doses of cangrelor,
a parenteral potent P2Y12 inhibitor and half-dose t-PA,
full-dose t-PA alone, and cangrelor alone administered to
STEMI patients were studied in relation to TMPG.
Although cangrelor þ t-PA was associated with a numeri-
cally higher incidence of TMPG 3, due to the small number
of patients enrolled in the STEP-AMI study, a deﬁnitive
effect of cangrelor on TMPG could not be established (12).
In the recently reported CHAMPION PHOENIX (Can-
grelor versus Standard Therapy to Achieve Optimal
Management of Platelet Inhibition) trial, conducted in
primarily troponin-negative patients, intravenous cangrelor
administered immediately before PCI was associated with
less intraprocedural thrombus than placebo (13).
In the current study, Kunadian et al. (4) examined the
relationship of oral P2Y12 inhibitor therapy to angiographic
outcomes in a large subgroup of patients enrolled in the
PLATO (Platelet Inhibition and Patient Outcomes) trial
who underwent PCI. Despite the fact that w20% patients
who received study drug before PCI did not have data that
allowed interpretation of the primary endpoint, the work of
Kunadian et al. (4) stands as the largest study (N ¼ 1,657) to
compare the effect of ticagrelor versus clopidogrel on
myocardial perfusion. The authors should also be congrat-
ulated for the thoroughness of their analyses. Their main
goal was to determine whether ticagrelor improved post-PCI
TMPG compared with clopidogrel therapy. In PLATO and
in the current PLATO angiographic substudy, there was
a high frequency of STEMI (w50%) and troponin-positive
patients (89%). Although the median duration between
randomization to angiography was overall short, wide vari-
ability in duration was particularly evident in the non-
STEMI–ACS population. Pre-randomization clopidogrel
administration was common. However, in the STEMI pop-
ulation, the time from randomization was very short (within
minutes). The investigators found that ticagrelor therapywas not associated with better angiographically determined
perfusion, irrespective of the method of assessment. In
addition to TMPG, other methods of perfusion assessment
(CTFC, TIMI ﬂow grade) failed to reveal a differential effect
of one P2Y12 inhibitor versus the other. Moreover, there was
no difference in TIMI thrombus grade between therapies.
Because GPIs are much more rapid and potent platelet
inhibitors than ticagrelor, it would be expected that ticagrelor
may have the greatest opportunity to achieve superior perfu-
sion characteristics than clopidogrel in the absence of GPI
therapy. However, the authors found the same results irre-
spective of GPI therapy. Finally, no differences in TMPG
were observed irrespective of clinical presentation (STEMI vs.
non-STEMI–ACS), time of assessment after ﬁrst dose of the
study drug (1 h or 2 h), and clopidogrel pre-treatment
status (13).
Should the ﬁndings of Kunadian et al. (4) argue against the
use of ticagrelor in ACS patients undergoing PCI? There are
several reasons why the investigators may have found what
they did. First, the overall antithrombotic effect of ticagrelor
compared with GPI may not be strong and rapid enough to
inﬂuence intraprocedural microvascular thrombosis deter-
mined by TMP. Second, in the STEMI population, the
duration from randomization to angiography occurred at
a median of w20 min. In stable non-PCI coronary artery
disease patients the pharmacodynamic effect of ticagrelor was
maximal at 2 h, and platelet inhibition was 41% at 30 min
post-administration (14). Recently, the pharmacodynamic
effect of ticagrelor has been reported to be delayed in STEMI
patients (15). Third, despite the inability to show differences
in myocardial perfusion angiographically, differences in
perfusion characteristics between therapies may exist. As
acknowledged by the authors, a potentially more sensitive
technique, such as delayed-enhancement magnetic resonance
imaging to measure infarct size used after PCI may have
detected differences between therapies. Finally, signiﬁcantly
increased coronary blood ﬂow velocity after adenosine infu-
sion was recently reported in healthy volunteers treated with
ticagrelor versus placebo. Although the latter phenomenon
has been attributed to an off-target effect, the inhibition of
adenosine reuptake by ticagrelor, the importance of this effect
with respect to myocardial perfusion in patients with ACS
undergoing PCI remains unproven (16).
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